Continuous Manufacturing Process for Human Use Helminth Infection Treatment

The project aims to develop a low-cost, sustainable manufacturing process for oxfendazole, a drug used to treat helminth infections, particularly in low- and middle-income countries. The initiative focuses on creating an effective treatment to combat diseases such as onchocerciasis (river blindness), which disproportionately affects Africa. By optimizing the synthesis of oxfendazole using green chemistry principles and Continuous Flow Technology (CFT), the project seeks to make the drug more affordable and accessible, potentially reducing treatment timelines and improving public health outcomes. This collaboration between DNDi and Kolon Life Science will enable large-scale production for human use.